NVCT vs RIGL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NVCT · Nuvectis Pharma$20.91 ▲ 17.74%
RIGL · Rigel Pharmaceuticals$39.65 ▼ 13.26%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NVCT +244.5%
- RIGL +14.8%
Head to head
| Metric | NVCT | RIGL |
|---|---|---|
| Price | $20.91 | $39.65 |
| Change today | ▲ 17.74% | ▼ 13.26% |
| Market cap | $719.07M | $746.61M |
| Return, 3 months | +10.8% | -4.8% |
| Return, year to date | +177.0% | -7.4% |
| Return, 1 year | +240.6% | +12.7% |
| P/E (TTM) | -10.5 | 2.5 |
| P/B | 5.7 | 1.7 |
| P/E percentile vs own 5y | 8th | 74th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -22.6% |
| Net profit growth (YoY) | -10.8% | -71.0% |
| Gross margin | – | 91.4% |
| Operating margin | – | 31.5% |
| Net margin | – | 116.3% |
| Return on equity | -233.3% | 126.9% |
| Analyst target vs. price | +64.2% | +63.9% |
| Analyst buy share | 100% | 50% |
| RSI (14) | 56 | 30 |
| 30-day volatility | 80.6% | 63.4% |
| Max drawdown, 1 year | -37.7% | -50.1% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RIGL is the largest of the group by market value.
- NVCT has returned the most over the past year.
- NVCT carries the lowest trailing P/E.
- RIGL has been the calmest stock over the last 30 days.